* Stoke Therapeutics Inc STOK.OQ STOK.O is expected
to show a
rise in quarterly revenue when it reports results on May 9
(estimated).
* The Bedford Massachusetts-based company is expected to
report
revenue of $40 million, according to the mean estimate from 9
analysts, based on Refinitiv data.
* Refinitiv's mean analyst estimate for Stoke Therapeutics
Inc is
for earnings of 36 cents per share. For the same quarter last
year, the company reported a loss of 46 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 11 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Stoke
Therapeutics Inc is $65, above its last closing price
of $14.06.
* Previous quarterly performance (using preferred earnings
measure
in US dollars).
QUARTER STARMINESM REFINITIV ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT IBES MET, SE %
E® ESTIMATE MISSED
Dec. 31 2021 -0.64 -0.62 -0.66 Missed -5.9
Sep. 30 2021 -0.61 -0.59 -0.61 Missed -3.8
Jun. 30 2021 -0.45 -0.47 -0.60 Missed -27.7
Mar. 31 2021 -0.44 -0.44 -0.46 Missed -4.5
Dec. -0.41 -0.42 -0.42 Met -0.2
31 2020
Sep. 30 2020 -0.44 -0.41 -0.41 Met 1
Jun. 30 2020 -0.36 -0.35 -0.39 Missed -10
Mar. 31 2020 -0.36 -0.36 -0.34 Beat 4.5
This summary was machine generated May 6 at 18:30 GMT. All
figures in US dollars unless otherwise stated